Early Follicular GnRH Antagonist Supplementation Improves Fertilization and Embryo Cleavage Rates in IVF-ET GnRH Antagonist Cycles
Overview
- Phase
- Phase 4
- Intervention
- Ganirelix
- Conditions
- Infertility
- Sponsor
- The Baruch Padeh Medical Center, Poriya
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- pregnancy rates
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results
Detailed Description
GnRH antagonist offers many advantages when used in IVF-ET treatment, however, it is suspected to yield lower pregnancy rate when compared with the long GnRH agonist protocol. Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results. Consecutive patients are prospectively enrolled and randomly assigned to the study and control groups. Patients with low ovarian reserve or with uterine distortion are excluded from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group are also treated with additional GnRH antagonist 0.25 mg/day on day 1, 2 and 3 of the menstrual cycle.
Investigators
Eligibility Criteria
Inclusion Criteria
- •infertility
- •IVF candidate
- •failure of previous IVF attempt
Exclusion Criteria
- •low ovarian reserve
- •untreated distortion of uterine cavity
- •medical contraindication for IVF treatment
Arms & Interventions
1
Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
Intervention: Ganirelix
Outcomes
Primary Outcomes
pregnancy rates
Time Frame: one cycle
Secondary Outcomes
- differences in hormonal levels(one cycle)
- differences in the basic treatment doses(one cycle)
- oocyte counts(one cycle)
- fertilization rate(one cycle)
- cleavage rate(one cycle)